DCVC Bio
Venture capitalPalo Alto · Seed–Growth · 16 people tracked
Investment thesis
DCVC Bio invests in founders marrying deep biological insight and engineering with large-scale computation to solve hard problems. Established in 2018, it backs foundational science and deep tech ventures across drug discovery (using synthetic biology, microfluidics, and machine learning to create novel therapies), agriculture (safer crop protection, reduced fertilizer use, renovated food systems), and bio-based alternative materials. The firm's team combines scientific expertise in genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI with decades of operational management experience, aiming to improve human health, make food production more sustainable, and slow climate change.
Source: firm website, verified Aug 24, 2026.
Team · 16 people
from the firm's website & curated
What they invest in
from 19 of 26 portfolio companiesBiotech ×15Deep Tech ×7AI & Machine Learning ×5Healthtech ×5Cleantech ×3Medical Devices ×3AgTech ×2Circular Economy ×2
HQs:United States×14Australia×1New Zealand×1
Investments · 26 tracked
founders shown can be your intro pathBy year:2025 · 52024 · 22023 · 22022 · 12021 · 212 dated
Fervo Energy develops next-generation geothermal technology using advanced drilling and sensing techniques to unlock carbon-free, 24/7 power generation in previously uneconomic locations.
CleantechClimate TechEnergyHouston, US
Tim Latimer(Founder & CEO)inJack Norbeck(Founder)in
BoardDavid Thomas Danielson(Director)inNicholas Walrod(Director)Ion Yadigaroglu(Director)
Co-investorsB Capital GroupB4 CapitalBaruch Future VenturesBeast VenturesBreakthrough Energy VenturesCarbon+13 more
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)
BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)
Board seatJohn Hamer· per SEC Form D
Co-investorsMPM BioImpactQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundDCVC (Data Collective)
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsRA CapitalDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.DCVC (Data Collective)
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsMPM BioImpactLilly Asia VenturesVersant VenturesDCVC (Data Collective)
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
BiotechData & InfrastructureEnterprise SoftwareMedia & EntertainmentDurham, US
Pieter Burger(Executive Officer, Director)Thomas Kaiser(Executive Officer, Director)
BoardChristopher Meldrum(Executive Officer, Director)inDennis Langer(Director)
Board seatJohn Hamer· per SEC Form D
Durham, US
Michele Fite(Executive Officer)Matthew Todd Rands(Executive Officer, Director)Chloe Pavely(Executive Officer)Paul Boyer(Executive Officer)Fayaz Khazi(Executive Officer, Director)Kartik Dharmadhikari(Director)
Board seatKiersten Stead· per SEC Form D · $25M raise · filed Jan 2024
San Diego, US
Board seatJohn Hamer· per SEC Form D · $55.2M raise · filed Mar 2023
Durham, US
Board seatKiersten Stead· per SEC Form D · $24.5M raise · filed Dec 2021
MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.
BiotechCircular EconomyNew MaterialsEmeryville, US
Philip Ross(Director)Michael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)
BoardThomas Grotkjaer(Director)
Board seatKiersten Stead· per SEC Form D
Co-investorsDCVC (Data Collective)Hemisphere Ventures LLCWireframe Ventures8VCAgFunderHumboldt+3 more
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSan Francisco, US
Charles Fisher(Founder & CEO)inAaron Smith(Founder)
Board seatJohn Hamer· per SEC Form D
Co-investors8VCAlumni VenturesBasecamp FundDCVC (Data Collective)Eisai Innovation, Inc.Flucas Ventures+5 more
AgZen develops real-time monitoring technology for crop spraying, analyzing droplet behavior to help growers and agricultural equipment manufacturers optimize application efficiency.
AgTechAI & Machine LearningFintechHardwareImpact & Social GoodMedia & Entertainment
Vishnu Jayaprakash(Founder)inKripa VaranasiMaher Damak
Co-investorsAstanor VenturesMaterial ImpactDCVC (Data Collective)Syngenta Group Ventures
CH4 Global develops greenhouse gas mitigation solutions centered on Asparagopsis seaweed, producing feed supplements that reduce enteric methane emissions from cattle for the livestock and agriculture industries.
AgTechCleantechClimate TechFoodTech
Steve Meller(CEO, President & Co-Founder)in
Co-investorsCleveland AvenueDCVC (Data Collective)AgFunder
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.
AI & Machine LearningBiotechDeep Tech
Co-investorsBioBritDCVC (Data Collective)Tenmile
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesMPM BioImpactRA CapitalDeerfield Management Company
Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions.
BiotechDeep TechChicago, US
Geoffrey Duyk(CEO)
Co-investorsDCVC (Data Collective)InVivium CapitalPortal Innovations
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM Ventures+1 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)Raymond Camahort(Director)
Co-investorsDCVC (Data Collective)Longwood FundNovo Holdings
NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.
Circular EconomyCleantechNew Materials
Co-investorsArc AngelsIcehouse VenturesLux CapitalThe Column Group
BiotechNew York, US
Jeff Goater(Executive Officer, Director)
BoardTim Kutzkey(Executive Officer, Director, Promoter)
Co-investorsDCVC (Data Collective)Lux CapitalThe Column Group
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtech
Co-investorsThe Column GroupLux Capital
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners Ventures5AM Ventures
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Frazier Life SciencesLongwood FundNovartis Venture FundOrbiMed+1 more
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical Devices
Ryan Clarke(Founder)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Draper AssociatesIllumina VenturesPortal Innovations
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioFervo EnergyNASDAQ: FRVO
Portfolio news
latest coverage across their companies
Sidewinder Therapeutics · techcrunch.com · Jul 30, 2026
Fervo Energy · investing.com · Jul 17, 2026
Fable · bankinfosecurity.com · Jul 8, 2026
nChroma Bio · contagionlive.com · Jun 25, 2026
Syntax · bizjournals.com · Jun 23, 2026
Grove Biopharma · xtalks.com · Jan 8, 2026
Nilo Therapeutics · clinicaltrialvanguard.com · Oct 9, 2025
Fund performance · per public LP disclosures
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| DCVC Bio II, L.P.LPs: Employees' Retirement System of Rhode Island | 2020 | — | 3.5% | 1.07x | 0.21x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has DCVC Bio made?
- DCVC Bio has 12 tracked investments, including 1 dated in the last 24 months.
- What stage does DCVC Bio invest at?
- DCVC Bio invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does DCVC Bio focus on?
- DCVC Bio focuses on Advanced Manufacturing, AgTech, AI & Machine Learning, Biotech, Climate Tech, Cybersecurity, Deep Tech, Defense Tech, Energy, Fintech, FoodTech, InsurTech, Longevity, New Materials, Quantum Computing, Space Tech.
- Where is DCVC Bio located?
- DCVC Bio is headquartered in Palo Alto, US.
- Who does DCVC Bio co-invest with?
- DCVC Bio most often shares deals with DCVC (Data Collective), Portal Innovations, B Capital Group, among 44 tracked co-investors.
Images
Similar investors
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner, backing emerging and established fund managers who invest in technology-focused Canadian companies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Radix Ventures is a venture capital firm founded in 2024 by entrepreneurs and tech investors, focused on empowering deep tech innovators across Europe, particularly Central and Eastern Europe.